ASX · CBL.AX
Control Bionics Limited
A$0.05+A$0.00 (+6.12%)
Control Bionics Limited’s quoted price sits in the lower half of its reported 52-week range, 45.26% below the high.
Loading market information…
ASX · NTI.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Neurotech International Limited’s quoted price sits in the upper half of its reported 52-week range, 19.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Neurotech International Limited’s next earnings report is currently expected on Mar 2, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neurotech International Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder. Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -A$0.01 |
| A$2.97K |
| Q4 2023 | Aug 30, 2023 | -A$0.00 | A$2.99K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.05+A$0.00 (+6.12%)
Control Bionics Limited’s quoted price sits in the lower half of its reported 52-week range, 45.26% below the high.
A$0.68-A$0.03 (-4.23%)
OncoSil Medical Ltd’s quoted price sits in the lower half of its reported 52-week range, 58.54% below the high.
A$0.05A$0.00 (0.0%)
BTC Health Limited’s quoted price sits in the lower half of its reported 52-week range, 27.14% below the high.
A$0.02-A$0.00 (-4.76%)
Althea Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
A$0.02A$0.00 (0.0%)
MedAdvisor Limited’s quoted price sits in the lower half of its reported 52-week range, 93.02% below the high.
A$0.01-A$0.00 (-6.67%)
Atomo Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.83% below the high.
A$0.02-A$0.00 (-4.0%)
Patrys Limited’s quoted price sits in the lower half of its reported 52-week range, 53.85% below the high.
A$0.10+A$0.01 (+5.56%)
Tissue Repair Ltd’s quoted price sits in the lower half of its reported 52-week range, 80.21% below the high.
